CMEonHIV.com is dedicated to providing online CME presentations (slides with voiceover) on HIV/AIDS for healthcare professionals given by local and international experts to keep you up-to-date on the ongoing developments in the field.
Conference
"104 weeks outcome of simplified regimens in PI-experienced patients" Dr. Franco Maggiolo (biography) English - 2003-04-11 - 27 minutes
Summary : Let us take a look at the philosophy behind treatment simplification, both from a physician and patient point of view. Physicians went from feeling hopeless with only mono- or dual- therapies in the 1990s, to excited upon the availability of many new treatment options, which were initially hoped to cure the disease. Eventually, though, an awareness grew that patients must live with their therapies for the rest of their lives, which fostered concern for the patient’s quality of life. According to patient reports, much of the drawbacks of ARV therapy can be overcome by simplifying the dosing schedule or reducing the pill burden. Switching therapy is one way to improve virologic outcome and tolerability, and ours is a long-term study, testing switching from a PI to either ABC or EFV, which shows significantly improved overall outcomes over 104 weeks (Maggiolo F et al.CID. In press).
Learning objectives : The participant will view the data of a long-term study of 104 weeks, testing the switch from PI to ABC or EFV (Maggiolo F et al.CID. In press):
1) Replacing the PI in patients with long-standing HIV RNA suppression, with EFV or ABC is generally better tolerated than continuing the PI.
2) This strategy maintains an optimal virological suppression.
3) Subjects pre-treated with dual ARV have a higher chance of virological failure if switched to ABC.
4) The lipid profile of patients on HAART may benefit from switching to a PI-sparing regimen, especially if based on ABC.
USER ACKNOWLEDGES AND AGREES THAT ALL DECISIONS MADE WITH THE ASSISTANCE OR USE OF THE SOFTWARE AND/OR THE WEBSITE AND/OR BASED ON CONTENT FOUND HEREIN WILL BE EXCLUSIVELY THE RESPONSIBILITY OF THE USER.
